Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56–6. http://www.ncbi.nlm.nih.gov/pubmed/22823436
Benros ME, Waltoft BL, Nordentoft M, Østergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders. JAMA Psychiatry. 2013;70:812. http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2013.1111
Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. Br J Psychiatry. 2016;208:138–45.
Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12:638–46. http://doi.wiley.com/10.1111/j.1399-5618.2010.00853.x
Nikkila H, Müller K, Ahokas A, Miettinen K, Andersson LC, Rimón R. Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res. 1995;14:215–21.
Müller N, Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: Relationship to negative symptomatology. Schizophr Res. 1995;14:223–8.
Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol. 1997;159:2994–9. http://www.jimmunol.org/content/159/6/2994
Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66:287–92. https://doi.org/10.1016/j.biopsych.2009.01.030
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med [Internet]. 2009;71:171–86. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006842-200902000-00006
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.
Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1121–8. http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2014.1332
Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans Pa, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7. http://www.nature.com/doifinder/10.1038/nature13595
Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–91. http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2014.1611
Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90:179–85.
Schuld A, Uhr M, Pollmächer T. Oligoclonal bands and specific antibody indices in human narcolepsy. Somnologie . 2004;8:71–4.
Stich O, Andres TA, Gross CM, Gerber SI, Rauer S, Langosch JM. An observational study of inflammation in the central nervous system in patients with bipolar disorder. Bipolar Disord. 2015;17:291–302.
Zachrisson OCG, Balldin J, Ekman R, Naesh O, Rosengren L, Ågren H, et al. No evident neuronal damage after electroconvulsive therapy. Psychiatry Res. 2000;96:157–65.
Bechter K, Herzog S, Behr W, Schüttler R. Investigations of cerebrospinal fluid in Borna disease virus seropositive psychiatric patients. Eur Psychiatry. 1995;10:250–8.
Bauer K, Kornhuber J. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur Arch Psychiatry Neurol Sci. 1987;236:257–9.
Endres D, Perlov E, Baumgartner A, Hottenrott T, Dersch R, Stich O, et al. Immunological findings in psychotic syndromes: a tertiary care hospital’s CSF sample of 180 patients. Front Hum Neurosci. 2015;9:476. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4564575&tool=pmcentrez&rendertype=abstract
Kirch DG, Kaufmann CA, Papadopoulos NM, Martin B, Weinberger DR. Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry. 1985;20:1039–46.
Bergquist J, Bergquist S, Axelsson R, Ekman R. Demonstration of immunoglobulin G with affinity for dopamine in cerebrospinal fluid from psychotic patients. Clin Chim Acta. 1993;217:129–42.
Nikkilä HV, Müller K, Ahokas A, Rimón R, Andersson LC. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res. 2001;49:99–105.
Müller N, Dobmeier P, Empl M, Riedel M, Schwarz M, Ackenheil M. Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry. 1997;12:294–9.
Kirch DG, Alexander RC, Suddath RL, Papadopoulos NM, Kaufmann CA, Daniel DG, et al. Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J Neural Transm. 1992;89:219–32.
Bruetsch W, Bahr M, Skobba J, Dieter W. The group of dementia praecox patients with an increase of the protein content of the cerebrospinal fluid. J Nerv Ment Dis. 1942;95:669–79.
Pazzaglia PJ, Post RM, Rubinow D, Kling Ma, Huggins TS, Sunderland T. Cerebrospinal fluid total protein in patients with affective disorders. Psychiatry Res. 1995;57:259–66. http://www.sciencedirect.com/science/article/pii/016517819502704Z%5Cn
Arias I, Sorlozano A, Villegas E, Luna J, de D, et al. Infectious agents associated with schizophrenia: A meta-analysis. Schizophr Res. 2012;136:128–36. http://www-clinicalkey-com.ep.fjernadgang.kb.dk/service/content/pdf/watermarked/1-s2.0-S0920996411005615.pdf?locale=en_US
Wang AK, Miller BJ Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2017; http://watermark.silverchair.com/api/watermark?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAigwggIkBgkqhkiG9w0BBgggIVMIICEQIBADCCAgoGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMEH01BKZZ8m-rh_TXAgEQgIIB22UkgfAIyiJWMQdFvpNMM9erz3gA6UB93lP9uMxq_uFtJ
Rimon R, Nishmi M, Halonen P. Serum and CSF antibody levels to herpes simplex type 1, measles and rubella viruses in patients with schizophrenia. Ann Clin Res. 1978;10:291–3.
Rimon RH, Halonen P, Lebon P, Heikkilä L, Frey H, Karhula P, et al. Antibrain antibodies and Interferon in the Serum and the Cerebrospinal Fluid of Patients with Schizophrenia1. Adv Biol Psychiatry. 1983;12:161–7. http://www.karger.com/?doi=10.1159/000408324
King DJ, Cooper SJ, Earle JAP, Martin SJ, McFerran NV, Wisdom GB. Serum and CSF antibody titres to seven common viruses in schizophrenic patients. Br J Psychiatry. 1985;147:145–9.
Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol. 1995;6:61–9.
Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry. 1993;150:1408–10.
Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimon R. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology. 1994;30:20–3. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=7969854
Leweke FM, Gerth CW, Koethe D, Klosterkötter J, Ruslanova I, Krivogorsky B, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254:4–8.
Nikkilä HV, Müller K, Ahokas A, Miettinen K, Rimón R, Andersson LC. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry. 1999;156:1725–9.
Albrecht P, Boone E, Torrey EF, Hicks JT, Daniel N. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. Lancet. 1980;2:769–72.
Torrey E, Albrecht P, Behr D. Permeability of the blood-brain barrier in psychiatric patients. Am J Psychiatry. 1985;142:657–8.
Hoerster SJ, Hillman F, Bohls S, Lara F, Thurman N. Cerebrospinal fluid in mental diseases (a study using paper electrophoresis). Dis Nerv Syst. 1963;24:357–60.
Selecki B, Todd P, Westwood A, Kraus J. Cerebro-spinal fluid and serum protein profiles in deteriorated epileptics, mental defectives with epilepsy, and schizophrenics. Med J Aust. 1964;2:751–3.
Shanmugam A. A study of cerebrospinal fluid proteins in schizophrenia. J Indian Med Assoc. 1971;57:206–8.
Deutsch SI, Mohs RC, Levy MI, Rothpearl AB, Stockton D, Horvath T, et al. Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer’s disease and normals. Biol Psychiatry. 1983;18:1363–73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6661467.
Nikkilä HV, Ahokas A, Wahlbeck K, Rimón R, Andersson LC. Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation. Neuropsychobiology. 2002;46:169–72. www.karger.com.
Torrey E, Yolken R, Winfrey J. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science. 1982;216:892–4. http://www.jstor.org/stable/1687554%5Cn
Pitts AF, Carroll BT, Gehris TL, Kathol RG, Samuelson SD. Elevated CSF protein in male patients with depression. Biol Psychiatry. 1990;28:629–37.
Levine J, Barak Y, Chengappa K, Rapoport A, Antelman S, Barak V. Low CSF soluble interleukin 2 receptor levels in acute depression. Short Commun J Neural Transm. 1999;106:1011–5.
Gotlieb-Stematsky T, Zonis J, Arlazoroff A, Mozes T, Sigal M, Szekely AG. Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients. Arch Virol. 1981;67:333–9.
Kumar A, Tewari SC, Lal N, Trivedi JK, Bahuguna LM. A study of abnormal CSF total proteins and immunoglobulins levels in patients of depression. Indian J Physiol Pharmacol. 1986;30:103–6.
Leonardi A, Cocito L, Tabaton M, Bartolini A, Roccatagliata G. CSF and serum IgG and albumin in schizophrenics. IRCS. Med Sci. 1982;10:812–3.
Axelsson R, Martensson E, Alling C. Impairment of the blood-brain barrier as an aetiological factor in paranoid psychosis. Br J Psychiatry. 1982;141:273–81.
Tiwari SG, Lal N, Trivedi JK, Sayeed J, Bahauguna LM. Immunoglobulin patterns in schizophrenic patients. Indian J Psychiatry. 1984;26:223–8. http://www.ncbi.nlm.nih.gov/pubmed/21965989%5Cn
Delisi LE, Weinberger DR, Potkin S, Neckers LM, Shiling DJ, Wyatt RJ. Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients. Br J Psychiatry. 1981;139:513–8.
Schwarz MJ, Ackenheil M, Riedel M. Norbert Müller. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett. 1998;253:201–3.
Tiwari SG, Lal N, Trivedi JK, Chaturvedi UC, Varma SL, Bahauguna LM. Immunoglobulins and viral antibodies in depressive patients. Indian J Psychiatry. 1990;32:318–23.
Zhu H, Wang D, Liu X. The reduction of CSF tumor necrosis factor alpha levels in schizophrenia: no correlations with psychopathology and coincident metabolic characteristics. Neuropsychiatr Dis Treat. 2016;12:2869–74.
Libíková H, Breier S, Kocisová M, Pogády J, Stünzner D, Ujházyová D. Assay of interferon and viral antibodies in the cerebrospinal fluid in clinical neurology and psychiatry. Acta Biol Med Ger. 1979;38:879–93. http://www.ncbi.nlm.nih.gov/pubmed/525159
Libíkowa H, Stancek D, Wiedermann V, Hasto J, Breier S. Psychopharmaca and electroconvulsive therapy in relation to viral antibodies and interferon. Exp Clin Study Arch Immunol Ther Exp. 1977;25:641–9.
Libíková H, Pogady J, Rajcani J, Skodacek I, Ciampor F, Kocisova M. Latent herpesvirus hominis 1 in the central nervous system of psychotic patients. Acta Virol. 1979;23:231–9. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=41436.
Roy A, Pickar D, Ninan P, Hooks J, Paul SM. A search for interferon in the CSF of chronic schizophrenic patients. Am J Psychiatry. 1985;142:269.
Levine J, Barak Y, Chengappa K, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:171–6. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstractBuch&ArtikelNr=26615&ProduktNr=226282
Stübner S, Schön T, Padberg F, Teipel SJ, Schwarz MJ, Haslinger A, et al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: No alteration of soluble gp130. Neurosci Lett. 1999;259:145–8.
Hestad KA, Engedal K, Whist JE, Aukrust P, Farup PG, Mollnes TE, et al. Patients with depression display cytokine levels in serum and cerebrospinal fluid similar to patients with diffuse neurological symptoms without a defined diagnosis. Neuropsychiatr Dis Treat. 2016;12:817–22.
Srikanth S, Ravi V, Poornima KS, Shetty KT, Gangadhar BN, Janakiramaiah N. Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic severity. Biol Psychiatry. 1994;36:517–21.
Rimon R, Ahokas A, Palo J. Serum and cerebrospinal fluid antibodies to cytomegalovirus in schizophrenia. Acta Psychiatr Scand. 1986;73:642–4.
Sierra-Honigmann AM, Carbone KM, Yolken RH. Polymerase chain reaction (PCR) search for viral nucleic acid sequences in schizophrenia. Br J Psychiatry. 1995;166:55–60. http://www.ncbi.nlm.nih.gov/pubmed/7894877
Torrey EF, Peterson MR, Brannon WL, Carpenter WT, Post RM, Van Kammen DP. Immunoglobulins and viral antibodies in psychiatric patients. Br J Psychiatry. 1978;132:342–8.
Shrikhande S, Hirsch SR, Coleman JC, Reveley MA, Dayton R. Cytomegalovirus and schizophrenia. A test of a viral hypothesis. Br J Psychiatry. 1985;146:503–6.
van Kammen DP, Mann L, Scheinin M, van Kammen WB, Linnoila M. Spinal fluid monoamine metabolites and anti-cytomegalovirus antibodies and brain scan evaluation in schizophrenia. Psychopharmacol Bull. 1984;20:519–22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6089252
Bartova L, Rajcani J, Pogady J. Herpes simplex virus antibodies in the cerebrospinal fluid of schizophrenic patients. Acta Virol. 1987;31:443–6.
Karlsson H, Bachmann S, Schroder J, McArthur J, Torrey EF, Yolken RH. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci. 2001;98:4634–9. http://www.pnas.org.ep.fjernadgang.kb.dk/content/98/8/4634.full.pdf
Deuschle M, Bode L, Heuser I, Schmider J, Ludwig H. Borna disease virus proteins in cerebrospinal fluid of patients with recurrent depression and multiple sclerosis. Lancet. 1998;352:1828–9. http://www.ncbi.nlm.nih.gov/pubmed/12589391
Samuelson SD, Winokur G, Pitts AF. Elevated cerebrospinal fluid protein in men with unipolar or bipolar depression. Biol Psychiatry. 1994;35:539–44. http://www.ncbi.nlm.nih.gov/pubmed/8038297
Pandey RS, Gupta AK, Chaturvedi UC. Autoimmune model of schizophrenia with special reference to antibrain antibodies. Biol Psychiatry. 1981;16:1123–36. http://www.ncbi.nlm.nih.gov/pubmed/6186298
Endres D, Dersch R, Hottenrott T, Perlov E, Maier S, van Calker D, et al. Alterations in cerebrospinal fluid in patients with bipolar syndromes. Front Psychiatry. 2016;7:1–8. http://journal.frontiersin.org/article/10.3389/fpsyt.2016.00194/full
Endres D, Perlov E, Dersch R, Baumgartner A, Hottenrott T, Berger B, et al. Evidence of cerebrospinal fluid abnormalities in patients with depressive syndromes. J Affect Disord. 2016;198:178–84. http://linkinghub.elsevier.com/retrieve/pii/S0165032716301136
Kern S, Skoog I, Börjesson-Hanson A, Blennow K, Zetterberg H, Östling S, et al. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav Immun. 2014;41:55–8. https://doi.org/10.1016/j.bbi.2014.05.006
McAllister CG, Van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995;152:1291–7.
El-Mallakh RS, Suddath RL, Wyatt RJ. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:383–91.
Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated Schizophrenia subtype. Neuropsychopharmacology. 2003;28:1515–20. http://www.nature.com/doifinder/10.1038/sj.npp.1300217.
Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, Flax J, et al. Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology. 2013;38:853–62. https://doi.org/10.1016/j.psyneuen.2012.09.010
Van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1999;87:129–36.
Yao JK, Sistilli CG, Van Kammen DP. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot Essent Fat Acids. 2003;69:429–36.
Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401–6.
Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40:126–33. http://jpn.ca/vol40-issue2/40-2-126/
Isgren A, Jakobsson J, Pålsson E, Ekman CJ, Johansson AGM, Sellgren C, et al. Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain Behav Immun. 2015;43:198–204. https://doi.org/10.1016/j.bbi.2014.10.001
Janelidze S, Suchankova P, Ekman A, Erhardt S, Sellgren C, Samuelsson M, et al. Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. Acta Psychiatr Scand. 2015;131:269–78.
Zetterberg H, Jakobsson J, Redsäter M, Andreasson U, Pålsson E, Ekman CJ, et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. 2014;217:143–6. https://doi.org/10.1016/j.psychres.2014.03.045
Gudmundsson P, Skoog I, Waern M, Blennow K, Pálsson S, Rosengren L, et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry. 2007;15:832–8.
Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, et al. Activation of brain interleukin-1β in schizophrenia. Mol Psychiatry. 2009;14:1069–71. https://doi.org/10.1038/mp.2009.52
Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: Prevalence and associated diseases. J Neurol. 2005;252:1067–73.
Kranaster L, Koethe D, Hoyer C, Meyer-Lindenberg A, Leweke FM. Cerebrospinal fluid diagnostics in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2011;261:529–30. https://doi.org/10.1007/s00406-011-0193-7
Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction. J Psychiatr Res. 2010;44:321–30. http://linkinghub.elsevier.com/retrieve/pii/S0022395609001848
Reiber H, Peter JB. Cerebrospinal fluid analysis: disease related data patterns and evaluation progams. J Neurol Sci. 2001;184:101–22. www.elsevier.com
Powell TR, Gaspar H, Chung R, Keohane A, Gunasinghe C, Uher R, et al. Assessing 42 inflammatory markers in 321 control subjects and 887 major depressive disorder cases: BMI and other confounders and overall predictive ability for current depression. Biorxiv. 2018. https://doi.org/10.1101/327239
Wright BLC, Lai JTF, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol. 2012;259:1530–45.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663–71.
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016; http://www.nature.com/doifinder/10.1038/mp.2016.3%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/26903267
Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in Schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63:801–8. http://ac.els-cdn.com.ep.fjernadgang.kb.dk/S0006322307009481/1-s2.0-S0006322307009481-main.pdf?_tid=a46b1c14-9ec4-11e7-8a0b-00000aacb362&acdnat=1505995487_8e9516a45237483ad0684a89e933556b
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57. http://ac.els-cdn.com.ep.fjernadgang.kb.dk/S0006322309012293/1-s2.0-S0006322309012293-main.pdf?_tid=eb18a960-9ec4-11e7-a5a7-00000aab0f6b&acdnat=1505995605_cab60f388110f8409eec8777f7c4680f
Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry. 2016;6:e777 https://doi.org/10.1038/tp.2016.40
Saija A, Princi P, Imperatore C, De Pasquale R, Costa G. Ageing influences haloperidol‐induced changes in the permeability of the blood‐brain barrier in the rat. J Pharm Pharmacol. 1992;44:450–2.
Heiser P, Enning F, Krieg J, Vedder H. Effects of haloperiodol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro. J Psychopharmacol. 2007;21:851–6.
Hirata-Hibi M, Higashi S, Tachibana T, Watanabe N. Stimulated lymphocytes in schizophrenia. Arch Gen Psychiatry. 1982;39:82–7.
Torrey EF, Upshaw YD, Suddath R. Medication effect on lymphocyte morphology in schizophrenia. Schizophr Res. 1989;2:385–90.
Elmorsy E, Al-Ghafari A, Almutairi FM, Aggour AM, Carter WG. Antidepressants are cytotoxic to rat primary blood brain barrier endothelial cells at high therapeutic concentrations. Toxicol Vitr. 2017;44:154–63. http://ac-els-cdn-com.ep.fjernadgang.kb.dk/S0887233317301972/1-s2.0-S0887233317301972-main.pdf?_tid=b6a8f7ff-3cff-4677-8d0b-27bc0a473af5&acdnat=1523906889_5e2d2f1a2f414f263ebabf8b28b253b1
Lee JY, Kim HS, Choi HY, Oh TH, Yune TY. Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury. Brain. 2012;135:2375–89.
Krogh J, Benros ME, Jørgensen MB, Vesterager L, Elfving B, Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014;35:70–6. https://doi.org/10.1016/j.bbi.2013.08.014
Yoon H-K, Kim Y-K, Lee H-J, Kwon D-Y, Kim L. Role of cytokines in atypical depression. Nord J Psychiatry. 2012;66:183–8. https://doi.org/10.3109/08039488.2011.611894
Köhler-Forsberg O, Buttenschøn HN, Tansey KE, Maier W, Hauser J, Dernovsek MZ, et al. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain Behav Immun. 2017;62:344–50. http://ac.els-cdn.com.ep.fjernadgang.kb.dk/S0889159117300624/1-s2.0-S0889159117300624-main.pdf?_tid=5870ce64-9611-11e7-b44a-00000aab0f01&acdnat=1505038870_96534e22a803f45c0f79d9afbfc1f299
Roos R, Davis K, Meltzer H. Immunoglobulin studies in patients with psychiatric diseases. Arch Gen Psychiatry. 1985;42:124–8.
Harrington MG, Merril CA, Tone EF. Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons. Clin Chem. 1985;31:722–6.
Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res. 1997;25:123–9.
Vawter MP, Dillon-Carter O, Issa F, Wyatt RJ, Freed WJ. Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology. 1997;16:83–7. http://ac.els-cdn.com.ep.fjernadgang.kb.dk/S0893133X96001431/1-s2.0-S0893133X96001431-main.pdf?_tid=7a62b708-988c-11e7-9080-00000aacb35f&acdnat=1505311657_9ed50217b7d6719fed5b737be02343e4
Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res. 2007;90:41–51.
Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM, et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull. 2014;40:963–72.
Severance EG, Gressitt KL, Alaedini A, Rohleder C, Enning F, Bumb JM, et al. IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun. 2015;44:148–58. https://doi.org/10.1016/j.bbi.2014.09.009
Hampel H, Kötter HU, Möller H-J. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression. Alzheimer Dis Assoc Disord. 1997;11:78–87. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002093-199706000-00004
Hampel H, Kotter HU, Padberg F, Korschenhausen DA, Moller HJ Oligoclonal bands and blood--cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. [Internet]. Alzheimer disease and associated disorders. 1999;9–19. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10192637
Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord. 2004;79:285–9.
Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK, Svenningsson P. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol. 2010;257:524–32. https://link-springer-com.ep.fjernadgang.kb.dk/content/pdf/10.1007%2Fs00415-009-5353-6.pdf
Söderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, et al. Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. J Psychiatry Neurosci. 2011;36:114–8.
Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress Anxiety. 2012;29:32–8.
Ueno Y, Kuraishi F, Uematsu S, Tsuruoka T. Qualitative differences between protein in blood serum and in cerebrospinal fluid of psychotics—the polarographic and electrophoretic studies. Folia Psychiatr Neurol Jpn. 1968;22:167–84.
Preble OT, Torrey EF. Serum interferon in patients with psychosis. Am J Psychiatry. 1985;142:1184–6.